U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07886606) titled 'Cannabidiol in Opioid Use Disorder and Chronic Pain With Buprenorphine' on Oct. 06.
Brief Summary: This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with buprenorphine. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at l...